Published in Clinical Trials Week, September 5th, 2005
According to a study from the United States, "Liraglutide (NN2211) is a long-acting GLP-1 analogue, with a pharmacokinetic profile suitable for once-daily administration. This multicenter, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on body weight and glycemic control in subjects with type 2 diabetes. Subjects (BMI 27-42 kg/m2) with type 2 diabetes who were previously treated with an OAD (oral...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.